drugset / Trial / NCT01060579

Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

NCT01060579

Phase 2 Completed 217 enrolled Aerie Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

A 28 day study of the safety and efficacy of two concentrations of topical AR-12286 in treating ocular hypertension and open-angle glaucoma compared to latanoprost. Hypothesis: The ocular hypotensive efficacy of each dose of AR-12286 ophthalmic solution will not be different from that of an active control.

Timeline

Start
2010-02
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Latanoprost Small molecule 0.005 % Topical
Subject VEROSUDIL Small molecule 0.25 % Topical
Subject VEROSUDIL Small molecule 0.5 % Topical

Indications